Have a personal or library account? Click to login
Pharmacodynamics of julibroside J8 and J12 in inhibiting angiogenesis Cover

Pharmacodynamics of julibroside J8 and J12 in inhibiting angiogenesis

By: Hui Hua,  Xiaoping Zhang,  Dan Li,  Jie Zou and  Zhongwei Lv  
Open Access
|Feb 2017

Abstract

Background: Ablizia julibrissin could inhibit the proliferation of cancer cells in vitro and in vivo. However, the effects of the compositions Julibroside J8 and J12 on the angiogenesis are still poorly understood.

Objective: We compared the pharmacodynamics of julibroside J8 and J12 in inhibiting angiogenesis in vitro and in vivo.

Methods: Julibroside J8 and J12 were separated from the crude extract of Ablizia julibrissin. The effects of julibroside J8 and julibroside J12 on growth, migration, and matrigel tube formation of human microvascular endothelial cells (HMEC-1) were explored. In addition, the in vivo anti-angiogenic effect of julibroside J8 and J12 was evaluated on a chorioallantoic membrane (CAM).

Results: HMEC-1 cells showed dose-dependent inhibition of growth, migration, and tube formation, when treated with 0.5-4 μg/ml julibroside J8 or 0.1-0.5 μg/ml julibroside J12 respectively. The formation of microvessels on CAM was also inhibited by julibroside J8 or julibroside J12 at concentrations of 10-100 μg.egg-1 or 5-50 μg.egg-1 respectively.

Conclusion: Julibroside J12 confers more potent inhibitory effect on angiogenesis than julibroside J8 does.

DOI: https://doi.org/10.5372/1905-7415.0506.102 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Language: English
Page range: 755 - 764
Published on: Feb 4, 2017
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2017 Hui Hua, Xiaoping Zhang, Dan Li, Jie Zou, Zhongwei Lv, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.